The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
COUR Pharmaceuticals and Genentech Partner to Develop Tolerogenic Therapy for Autoimmune Disease
Dec 03, 2024•over 1 year ago
Contract Type
partnership
SkokiePharmaceutical Manufacturing
Description
COUR Pharmaceuticals has entered a strategic collaboration and licensing agreement with Genentech, a member of the Roche Group, for the development and commercialization of COUR’s proprietary tolerogenic nanoparticle treatments for an autoimmune disease. The agreement includes upfront and near-term milestone payments totaling $40 million, with the potential for further milestone payments exceeding $900 million and tiered royalties. The partnership aims to leverage COUR’s clinical success in autoimmune diseases and Genentech's world-class scientific expertise to have a significant impact on patient community with significant unmet needs.
Company Information
Company
COUR Pharmaceuticals
Location
Skokie, Illinois, United States
About
We are a group of dedicated scientific, medical, and business professionals who are driven to find treatments and cures to a variety of diseases. By attacking the disease directly with our novel nanoparticle-based technologies and working strategically with our medical and scientific partners we seek to provide treatments and cures previously unavailable to doctors and their patients.
SkokiePharmaceutical Manufacturing